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172. Risk Factors for 30-Day Mortality in Patients with Staphylococcus aureus 
Bacteremia at a Community Hospital: A Prospective Case–Control Study 
Abstract 
Background: 
Staphylococcus aureus bacteremia (SAB) is associated with 30-day all-cause mortality rates approaching 
20–30%. The purpose of this case–control study was to evaluate risk factors for 30-day mortality in 
patients with SAB at a community hospital. 
Methods: 
As part of an antimicrobial stewardship program (ASP) initiative mandating Infectious Diseases 
consultation for episodes of SAB, our ASP prospectively monitored all cases of SAB at a 341-bed 
community hospital in Jefferson Hills, PA from April 2017–February 2019. Cases included patients with 
30-day mortality from the initial positive blood culture. Only the first episode of SAB was included; 
patients were excluded if a treatment plan was not established (e.g., left against medical advice). Patient 
demographics, comorbidities, laboratory results, and clinical management of SAB were evaluated. 
Inferential statistics were used to analyze risk factors associated with 30-day mortality. 
Results: 
100 patients with SAB were included; 18 (18%) experienced 30-day mortality. Cases were older (median 
age 76.5 vs. 64 years, P <</em> 0.001), more likely to be located in the intensive care unit (ICU) at time of 
ASP review (55.6% vs. 30.5%, P = 0.043), and less likely to have initial blood cultures obtained in the 
emergency department (ED) (38.9% vs. 80.5%, P <</em> 0.001). Variables associated with significantly 
higher odds for 30-day mortality in univariate analysis: older age, location in ICU at time of ASP review, 
initial blood cultures obtained at a location other than the ED, and total Charlson Comorbidity Index (CCI). 
Variables with P <</em> 0.2 on univariate analysis were analyzed via multivariate logistic regression 
(Table 1). 
Conclusion: 
Results show that bacteremia due to MRSA and total CCI were not significantly associated with 30-day 
mortality in SAB, whereas older age was identified as a risk factor. Patients with initial blood cultures 
obtained at a location other than the ED were at increased odds for 30-day mortality on univariate 
analysis, which may raise concern for delayed diagnosis. 
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Rahul Mhaskar, MPH, PhD2; Doosup Shin, MD1;  
Chandrashekar Bohra, MD1 and Charurut Somboonwit, MD1; 1University of South 
Florida, Tampa, Florida; 2Morsani College of Medicine, University of South Florida, 
Tampa, Florida
Session: 37. Bacteremia, CLABSI, and Endovascular Infections
Thursday, October 3, 2019: 12:15 PM
Background.  Caring for hospitalized patients with infective endocarditis (IE) 
can be challenging due to the nature of the disease and its complications, underlying 
medical and psychiatric problems, socioeconomic status and environmental factors.
Some of these patients develop recurrent IE after the first episode treated. On-going 
intravenous (IV) drug use after hospital discharge is the highest predictive factor for 
recurrent IE. Besides IV drug use, there are limited data of other contributing factors to 
recurrent IE. Those factors may be modifiable during the first hospitalization to reduce 
the incidence of recurrent IE.
Methods.  A retrospective cohort study was conducted at a large tertiary acute 
care medical center in Tampa, Florida. All consecutive patients with IE with history of 
IV drug use from January, 2011 to December, 2017 were included. Basic demographic 
information, co-morbidities (diabetes, hypertension, chronic lung and kidney diseases, 
HIV, Hepatitis B and C status, coronary artery diseases), valves involved, length of stay, 
complications at their first IE episode such as septic shock and stroke were included. 
Groups were identified based on the first episode, first recurrence and second or more 
recurrences of IE.
Results.  A total of 106 patients were identified based on the inclusion criteria. 
The association between the type of valve infection (right side and left side) and IE 
recurrence was found to be statistically significant. (P = 0.003). Right side valves are 
prone to have recurrent IE episodes. People with recurrent IE were more likely to have 
septic shock (P = 0.02) and requiring intensive care unit (ICU) admissions (P < 0.001) 
during their first episode There was no statistically significant difference between other 
demographic information and recurrent endocarditis as well as other parameters such 
as organisms or type of substance used. (Table 1)
Conclusion.  Right-sided IE and presence of septic shock during their first episode of 
IE may be the predictors for recurrent IE. Interventions including closer follow-up, more 
aggressive septic shock recognition and management, socioeconomic assessment in addition 
to substance abuse treatments after discharge should be considered to prevent recurrent IE.
Disclosures. All authors: No reported disclosures.
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Background.  Monitoring bloodstream infections provides updates of the micro-
biology and antibiotic susceptibility trends. We elected to examine GNB-BSI.
Methods.  We retrospectively studied adults (≥18  years old) inpatients with 
gram-negative bacilli (GNB) bloodstream infection (BSI; January 1, 2010–December 
31, 2017), determined the demographics, onset place, microbiology and source. The 
results were stratified to study year and evaluated by the extended Mantel–Haenszel 
chi square for linear trends.
Results.  GNB were encountered in 4520/14314 (31.6%) positive blood cul-
ture (BC) accounting for 2811 BSI episodes (2291 patients) with a steadily increas-
ing rate (table). The 3 most common organisms were Escherichia coli (EC; 44.4%), 
Klebsiella pneumoniae (KP; 19.2%) and Pseudomonas aeruginosa (PA; 9.6%). GNB-
BSI rate increase was mainly in EC-BSI (P = 0.01). The rate of other GNB-BSI did 
not change. Source distribution of EC-BSI did not change and antibiotic resistance 
did not change.
Conclusion.  GNB-BSI is rising, primarily due to EC, without changes in source 
distribution or antibiotic susceptibility. Prospective studies to look at EC lineage and 
virulence factors are needed to determine the reason for EC-BSI rise.
Disclosures. All authors: No reported disclosures.
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Background.  Staphylococcus aureus bacteremia (SAB) is associated with 30-day 
all-cause mortality rates approaching 20–30%. The purpose of this case–control study 
was to evaluate risk factors for 30-day mortality in patients with SAB at a community 
hospital.
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Methods.  As part of an antimicrobial stewardship program (ASP) initiative man-
dating Infectious Diseases consultation for episodes of SAB, our ASP prospectively 
monitored all cases of SAB at a 341-bed community hospital in Jefferson Hills, PA 
from April 2017–February 2019. Cases included patients with 30-day mortality from 
the initial positive blood culture. Only the first episode of SAB was included; patients 
were excluded if a treatment plan was not established (e.g., left against medical advice). 
Patient demographics, comorbidities, laboratory results, and clinical management of 
SAB were evaluated. Inferential statistics were used to analyze risk factors associated 
with 30-day mortality.
Results.  100 patients with SAB were included; 18 (18%) experienced 30-day 
mortality. Cases were older (median age 76.5 vs. 64 years, P < 0.001), more likely 
to be located in the intensive care unit (ICU) at time of ASP review (55.6% vs. 
30.5%, P  =  0.043), and less likely to have initial blood cultures obtained in the 
emergency department (ED) (38.9% vs. 80.5%, P < 0.001). Variables associated 
with significantly higher odds for 30-day mortality in univariate analysis: older 
age, location in ICU at time of ASP review, initial blood cultures obtained at a lo-
cation other than the ED, and total Charlson Comorbidity Index (CCI). Variables 
with P < 0.2 on univariate analysis were analyzed via multivariate logistic regres-
sion (Table 1).
Conclusion.  Results show that bacteremia due to MRSA and total CCI were not 
significantly associated with 30-day mortality in SAB, whereas older age was identified 
as a risk factor. Patients with initial blood cultures obtained at a location other than the 
ED were at increased odds for 30-day mortality on univariate analysis, which may raise 
concern for delayed diagnosis.
Disclosures. All authors: No reported disclosures.
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Background.  The emergence of carbapenem-resistant Klebsiella pneumoniae 
(CR-Kp) presents significant clinical challenges with our limited antibiotic armament-
arium. Infective endocarditis caused by CR-Kp is rare, with few cases reported in the 
literature. The use of the novel β-lactam/β-lactamase inhibitor combination ceftazi-
dime–avibactam (CAZ-AVI) in this setting has only been described in one 2018 case 
in Italy. Guidance in how these novel antibiotics should be used becomes more prudent 
as the prevalence of complicated CR-Kp infections increases.
Methods.  A 51-year-old male with a past medical history of a gunshot wound 
to the neck, type 2 diabetes, and osteomyelitis status post right below-the-knee and 
left toe amputations presented to the emergency department with altered mental 
status and right upper extremity weakness. The patient’s hospital course was com-
plicated by hemorrhagic stroke, left above-the-knee amputation, and intraoperative 
cardiac arrest. Subsequently, blood cultures on hospital days 41 and 43 grew CR-Kp 
and a transthoracic echocardiogram (TTE) showed moderate to severe aortic 
regurgitation.
Results.  Antimicrobial therapy was changed from imipenem-cilastatin and 
colistin to CAZ-AVI and amikacin. The organism was found to be susceptible to 
CAZ-AVI and amikacin, intermediate to colistin, and resistant to all carbapenems. 
A transesophageal echocardiogram (TEE) confirmed the presence of a small mobile 
vegetation on the aortic valve with perforation and severe regurgitation. CAZ-AVI 
and amikacin were continued for two weeks, and then switched to CAZ-AVI and 
ertapenem for an additional four weeks. Follow-up blood cultures on and after day 
44 were negative for CR-Kp. A TTE performed after therapy completion no longer 
demonstrated aortic regurgitation; however, the valves were poorly visualized. The 
patient then suffered anoxic brain injury after a second cardiac arrest, thought to be 
unrelated to endocarditis. The patient’s family then decided on hospice care and the 
patient expired.
Conclusion.  We report the successful treatment of CR-Kp endocarditis with 
CAZ-AVI and amikacin for two weeks followed by CAZ-AVI and ertapenem for four 
weeks. This regimen can be a viable option for patients that present with this rare mul-
tidrug-resistant infection.
Disclosures. All authors: No reported disclosures.
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Background.  Durable mechanical circulatory support device (MCSD) use con-
tinues to grow. MCSD deep-seated infections are a serious complication. Removal of 
the infected hardware is not always possible.
Methods.  Single institution retrospective review of all culture-proven deep 
MCSD infection (pump and/or driveline) from 2009–2019. Patients were managed 
with intravenous (IV) and oral (PO) antibiotics; definitive surgical interventions 
included incision and drainage (I&D), device replacement, and heart transplant; and 
temporizing surgical measures were chronic chest tube (CCT) drainage for pump 
pocket and mediastinum and antibiotic impregnated bead implantation for driveline 
infection. Outcomes were analyzed.
Results.  Total of 29 patients identified, 23 (79%) were male. Median age 
at device implantation was 44 years (20–68). MCSD were 18 (62%) destination 
therapy and 11 (38%) bridge to transplant. MCSD included 1 Heartmate I, 17 
Heartmate II, 1 Heartmate III, 4 Heartware HVAD, and 6 Syncardia TAH. The 
median time to infection of 258 days (43–1551), affecting pump in 8 (28%), pump 
+ driveline in 13 (44%), and driveline in 8 (28%). Microorganisms were S. aureus 
in 17 (60%, MRSA 11 and MSSA 6); coag-negative staphylococci in 3 (10%); 
Viridans streptococci in 1; Serratia marcescens in 3; P. aeruginosa in 2; Klebsiella 
oxytoca in 1; Mycobacterium abscessus in 1 and C. albicans in 1. Antibiotics are 
given to 28 patients, 23 (80%) with initial IV for a median of 6 weeks (1–14) 
and 5 (17%) with initial PO, for a median of 7 weeks (2–20). Nineteen patients 
(83%) on IV received PO antibiotics after. 17 patients (61%) remained on chronic 
suppression antibiotics (13 PO, 2 IV, 2 PO and IV). Twenty-six (90%) patients 
had I&D, 6 (21%) had device replacement and 11 (38%) had transplant. Of 21 
patients with pump infection 16 (76%) had CCT drainage of pump pocket site or 
mediastinum for a median of 116 days (range 10–887 days). Of 21 patients with 
driveline infections, 6 (29%) had antibiotic impregnated bead implants. Overall 
survival at 90 days was 28/29 (95%) and 24/29 (83%) at 1 year. Infection-related 
mortality in Table 1.
Conclusion.  Deep MCSD infection remains a challenging clinical problem. CCT 
drainage (for pump) and antibiotic-impregnated bead implant (for driveline) may be 
temporizing options for patients unable to undergo timely device replacement or heart 
transplant.
Disclosures. All authors: No reported disclosures.
175. There Was a Fungus Among Us: A Cohort of Fungal Infectious Endocarditis 
Cases in East Tennessee
Morgan K. Morelli, MD1; William Lorson, DO1 and Mahmoud Shorman, MD2; 
1University of Tennessee Graduate School of Medicine, Knoxville, Tennessee; 
2University of Tennessee, Knoxville, Tennessee
Session: 37. Bacteremia, CLABSI, and Endovascular Infections
Thursday, October 3, 2019: 12:15 PM
Background.  Fungal infective endocarditis (IE) represents less than 2% of all IE 
cases, but it carries a mortality rate as high as 50%. While cases of IE are on the rise 
in recent years due to the increased prevalence of persons who inject drugs (PWID), 
there are few published studies of fungus as the cause. Candida species is the most 
likely fungal pathogen in IE. Known risk factors include prosthetic heart valves, 
healthcare-associated infections, and injection drug use. Since fungi are a rare culprit 
in endocarditis, there is little information on incidence, treatment recommendations, 
and outcomes.
Methods.  A retrospective cohort of patients with Candida IE was analyzed be-
tween October 2013 and September 2018 at a university hospital in East Tennessee. 
Demographic, microbiologic, substance use status, mortality, and echocardiographic 
data were collected.
Results.  Nine patients with Candida IE met inclusion criteria. Mean age was 37, 
67% were males. Risk factors included PWID, oral opioid abuse, previous valve surgery 
and autoimmune disease. 5 (55%) were caused by Candida albicans, 3 (33.3%) Candida 
paraipsalosis, and 1 (11%) grew both Candida tropicalis and albicans. Valves involved: 
4 (66.7%) native tricuspid, 2 (22%) native aortic. 2 (22%) had native mitral, 1 (11%) 
had both tricuspid and mitral valve involvement. Echinocandins were used in 5 (55%) 
and 2 (22%) underwent surgery. There was 1 (11%) in-hospital mortality and 2 (22%) 
within 1 year of discharge (Table 1).
Conclusion.  Fungal IE is a rare disease with high mortality and increasing in-
cidence, especially in PWID. High index of suspicion is required for early diagnosis. 
Treatment is traditionally a combination of surgery and antifungal therapy. Although, 
medical treatment alone can be successful in patients who are not surgical candidates, 
such as in PWID.
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